CCL23 and COVID-19: A high number of circulating DEspRhigh neutrophils is associated with an increased level of CCL23 and NETosing neutrophils in critically ill COVID-19 patients, identifying DEspRhigh neutrophils as an intermediate biomarker to track in clinical trials of therapies for COVID-19 and a new potential therapeutic target for the prevention of immune cell-driven hyperinflammation.